Since APP palmitoylation seems to enhance the amyloidogenic pathway, the loss of a depalmitoylating enzyme such as PPT1 might result in an increased amyloid production; this hypothesis is line with the observed clinical phenotype of the carrier, an early onset familial AD patient. This evidence concerns the gene PPT1 and Alzheimer disease.